The selective GSK-3 peptide inhibitor, L803-mts, increased glucose transporter type 4 (GLUT4) expression in murine muscle tissue; the transporter is altered in DMD and seems to be involved in DMD insulin resistance [71,72]. This evidence concerns the gene SLC2A4 and Duchenne muscular dystrophy.